Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Akorn Inc Issues FY 2013 Guidance; Earnings Guidance Below Analysts' Estimates
Akorn Inc announced that for fiscal 2013, it expects total revenues to be $325-335 million, GAAP net income to be $53-57 million, GAAP net income per diluted share to be $0.46-$0.50 per share, adjusted net income to be $65-$69 million and adjusted net income per diluted share to be $0.57-$0.61 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $331 million, net income of $72 million and EPS of $0.66 for fiscal 2013.
Latest Key Developments in Pharmaceuticals
- Nattopharma ASA Maintains FY 2013 Revenue Guidance
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Share this
- Link this
- Digg this
Follow Reuters